Table 5.

Analysis of the different clinical characteristics and outcomes according to rs4646 and rs12592697 polymorphisms in the CYP19A1 in premenopausal women with breast cancer.

rs4646	CC (N = 85)	CT/TT (N = 86)
ER
Positive	27/44 (61.4%)	34/53 (64.2%)	0.78
Negative	17/44 (38.6%)	19/53 (35.8%)
PR
Positive	25/44 (56.8%)	30/53 (56.6%)	0.98
Negative	19/44 (43.2%)	23/53 (43.4%)
ER+/PR+	25/43 (58.1%)	30/51 (58.8%)	0.96
HER2+	9/41 (21.9%)	11/50 (22%)	0.99
Triple negative	12/44 (27.3%)	17/53 (32.1%)	0.61
Progressive disease	9/44 (20.5%)	15/53 (28.3%)	0.37
Stage at diagnosis
Stage 0–II	35/46 (76.1%)	36/55 (65.5%)	0.24
III–IV	11/46 (23.9%)	19/55 (34.5%)
Estradiol (pg/ml)	36.2 ± 26.2	37.8 ± 44.2	0.89
rs12592697	CC	CC/TT
ER
Positive	22/31 (71.0%)	39/66 (59.1%)	0.26
Negative	9/31 (29.0%)	27/66 (40.9%)
PR
Positive	19/30 (63.3%)	36/67 (53.4%)	0.38
Negative	11 (36.7%)	31/67 (46.3%)
ER+/PR+	19/30 (63.3%)	36/65 (55.4%)	0.47
HER2+	5/26 (19.2%)	15/65 (23.1%)	0.69
Triple negative	9/31 (29.0%)	20/66 (30.3%)	0.90
Progressive disease	8/31 (25.8%)	16/66 (24.2%)	0.87
Stage at diagnosis (n = 303)
Stage 0–II	20/30 (66.7%)	51/70 (72.9%)	0.40
III–IV	11/31 (35.5%)	19/70 (27.1%)
Estradiol (pg/ml)	47.2 ± 61.1	33.6 ± 24.4	0.30

Formats of cell entries are mean ± SD or frequency/n (%), ER+, Estrogen receptor positive; PR+, progesterone receptor positive; HER2, Human epidermal growth factor receptor 2.